# Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

> clinical trial · VERIFIED · 2026-07-24

Status: ACTIVE_NOT_RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Myelodysplastic Syndromes

- Company: Novartis Pharmaceuticals
- Sector: Myelodysplastic Syndromes
- Primary source: https://clinicaltrials.gov/study/NCT05201066

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.